Fortress Biotech, Inc.
FBIO
$2.72
$0.010.37%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 12.05% | -0.90% | |||
| Total Other Revenue | 651.28% | 800.00% | |||
| Total Revenue | 16.71% | -0.25% | |||
| Cost of Revenue | 2.81% | 33.22% | |||
| Gross Profit | 26.83% | -15.68% | |||
| SG&A Expenses | 30.92% | 7.90% | |||
| Depreciation & Amortization | -13.94% | 5.73% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.81% | 13.94% | |||
| Operating Income | -29.29% | -61.60% | |||
| Income Before Tax | -99.35% | 2,390.26% | |||
| Income Tax Expenses | -93.76% | 728.92% | |||
| Earnings from Continuing Operations | -99.56% | 2,641.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 96.01% | -1,934.86% | |||
| Net Income | -100.42% | 2,903.48% | |||
| EBIT | -29.29% | -61.60% | |||
| EBITDA | -37.16% | -79.52% | |||
| EPS Basic | -102.27% | 1,784.17% | |||
| Normalized Basic EPS | -100.87% | 2,587.75% | |||
| EPS Diluted | -102.84% | 1,482.35% | |||
| Normalized Diluted EPS | -101.06% | 2,142.68% | |||
| Average Basic Shares Outstanding | 0.79% | 3.81% | |||
| Average Diluted Shares Outstanding | -17.24% | 26.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||